PHR1499

フルルビプロフェン

Pharmaceutical Secondary Standard; Certified Reference Material

• 別名: (±)-2-フルオロ-α-メチル-4-ビフェニル酢酸, L-790,330
• 化学式: C₆H₅C₆H₃(F)CH(CH₃)CO₂H
• CAS番号: 5104-49-4
• 分子量: 244.26
• EC Number: 225-827-6
• MDL番号: MFCD00079303
• UNSPSCコード: 41116107
• PubChem Substance ID: 329823420
• NACRES: NA.24

特性

• グレード: certified reference material; pharmaceutical secondary standard
• 品質水準: 300
• 認証: traceable to Ph. Eur. F0285200; traceable to USP 1285750
• APIファミリー: flurbiprofen
• CofA: current certificate can be downloaded
• 包装: pkg of 500 mg
• テクニック: HPLC: suitable; gas chromatography (GC): suitable
• mp: 110-112 °C (lit.)
• アプリケーション: pharmaceutical (small molecule)
• フォーマット: neat
• 保管温度: 2-30°C
• SMILES記法: CC(C(O)=O)c1ccc(c(F)c1)-c2ccccc2
• InChI: 1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
• InChI Key: SYTBZMRGLBWNTM-UHFFFAOYSA-N
• 遺伝子情報: human ... PTGS1(5742) , PTGS2(5743)

詳細

詳細

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Flurbiprofen is a non-selective, non-steroidal anti-inflammatory drug (NSAID) that is widely used against rheumatoid arthritis. It is also effective against vernal keratoconjunctivitis, post-operative ocular inflammation, herpetic stromal keratitis, excimer laser photorefractive keratectomy and ocular gingivitis.

アプリケーション

Flurbiprofen may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations and biological samples by various analytical techniques.

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

生物化学的／生理学的作用

フルルビプロフェンはシクロオキシゲナーゼ（COX）阻害薬であり、プロスタグランジン合成経路における、アラキドン酸からプロスタグランジンG2（PGG2）へ、PGG2からプロスタグランジンH2（PGH2）への変換に関与する酵素です。本化合物は、炎症、疼痛、腫脹および発熱の原因となるプロスタグランジンを減少させます。フルルビプロフェンはCOX-1および-2両方の活性を阻害します。 Sエナンチオマーはプロスタグランジン合成を阻害し、抗炎症作用および鎮痛作用の両方を有していますが、Rエナンチオマーはプロスタグランジン合成を阻害せず、鎮痛作用のみ示します。

アナリシスノート

このような2次標準は、入手可能な場合にはUSP、EP、BPの1次標準にマルチトレーサビリティを提供します。

その他情報

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

脚注

To see an example of a Certificate of Analysis for this material enter LRAA3047 in the slot below. This is an example certificate only and may not be the lot that you receive.

おすすめ製品

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

安全性情報

• ピクトグラム: GHS06
• シグナルワード: Danger
• 危険有害性情報: H301
• 注意書き: P301 + P310
• 危険有害性の分類: Acute Tox. 3 Oral
• 保管分類コード: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable